Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...

Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Biohaven Ltd. (BHVN – ...

SAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer ...

Leerink raised the firm’s price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...